Kingdon Capital Management, L.L.C. Syndax Pharmaceuticals Inc Transaction History
Kingdon Capital Management, L.L.C.
- $874 Million
- Q1 2025
A detailed history of Kingdon Capital Management, L.L.C. transactions in Syndax Pharmaceuticals Inc stock. As of the latest transaction made, Kingdon Capital Management, L.L.C. holds 2,000,000 shares of SNDX stock, worth $25 Million. This represents 2.81% of its overall portfolio holdings.
Number of Shares
2,000,000
Previous 2,000,000
-0.0%
Holding current value
$25 Million
Previous $26.4 Million
7.03%
% of portfolio
2.81%
Previous 4.31%
Shares
4 transactions
Others Institutions Holding SNDX
# of Institutions
239Shares Held
102MCall Options Held
1.36MPut Options Held
618K-
Kynam Capital Management, LP Princeton, NJ8.52MShares$106 Million8.82% of portfolio
-
Black Rock Inc. New York, NY7.91MShares$98.7 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.87MShares$60.8 Million0.0% of portfolio
-
Eversept Partners, LP New York, NY4.21MShares$52.6 Million5.73% of portfolio
-
Steven Cohen Point72 Asset Management, L.P. | Stamford, Ct4.01MShares$50 Million0.12% of portfolio
About Syndax Pharmaceuticals Inc
- Ticker SNDX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 56,565,200
- Market Cap $706M
- Description
- Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are SNDX-5613, which is in phase 1/2 clinical trial targeting the binding interaction of Menin with the mixed lineage leukemia 1 protein for the treatment of MLL-rearranged (MLLr) and nucleophosmin...